Pharmaceutical companies stalling on new plans

Published: 2011-01-07 06:58:00

Updated: 2011-01-07 06:58:00

Reflecting increasing market uncertainty in the domestic market, pharmaceutical drug makers are still delaying the formulation of their business plans for this year.

Companies usually flesh out their sales targets, profit goals, investment scale and other key components of their plans finaliz...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK